Table 2 Relationship between SFXN1downregulation and clinicopathological factors in viral cases.
From: Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma
Variable | SFXN1high (n = 39) | SFXN1low (n = 22) | P-value |
|---|---|---|---|
Age (median) | 70 (49–82) | 74 (37–86) | 0.18 |
Sex | |||
 Male | 27 | 17 | 0.50 |
 Female | 12 | 5 |  |
Viral infection | |||
 HBV | 7 | 7 | 0.21 |
 HCV | 32 | 15 |  |
Alcohol | 17 | 13 | 0.24 |
Diabetes | 8 | 8 | 0.18 |
Dyslipidemia | 2 | 4 | 0.23 |
Obesity | |||
 BMI > 25 | 13 | 7 | 0.90 |
 BMI ≤ 25 | 26 | 15 |  |
Plt | |||
 < 10 × 104/μL | 6 | 4 | 0.78 |
 ≥ 10 × 104/μL | 33 | 18 |  |
PT | |||
 < 80% | 6 | 4 | 0.78 |
 ≥ 80% | 33 | 18 |  |
Alb | |||
 < 3.5 g/dL | 7 | 2 | 0.57 |
 ≥ 3.5 g/dL | 32 | 20 |  |
AST | |||
 > 40 IU/L | 23 | 6 | 0.017* |
 ≤ 40 IU/L | 16 | 16 |  |
ALT | |||
 > 40 IU/L | 17 | 4 | 0.045* |
 ≤ 40 IU/L | 22 | 18 |  |
T-Bil | |||
 > 1.0 mg/dL | 9 | 6 | 0.71 |
 ≤ 1.0 mg/dL | 30 | 16 |  |
ICG | |||
 > 15% | 18 | 10 | 0.96 |
 ≤ 15% | 21 | 12 |  |
α-Fetoprotein (AFP) | |||
 > 200 ng/mL | 10 | 8 | 0.38 |
 ≤ 200 ng/mL | 29 | 14 |  |
PIVKA-II | |||
 > 100 mAU/mL | 26 | 13 | 0.55 |
 ≤ 100 mAU/mL | 13 | 9 |  |
Child–Pugh grade | |||
 A | 39 | 22 | 1.00 |
 B | 0 | 0 |  |
Tumor size | |||
 > 5 cm | 9 | 5 | 0.98 |
 ≤ 5 cm | 30 | 17 |  |
Tumor number | |||
 Solitary | 30 | 17 | 0.98 |
 Multiple | 9 | 5 |  |
Differentiation | |||
 Well | 15 | 6 | 0.37 |
 Poorly/moderately | 24 | 16 |  |
Portal vein invasion | |||
 0 | 26 | 12 | 0.16 |
 1, 2 | 10 | 10 |  |
 3, 4 | 3 | 0 |  |
Liver status | |||
 NL | 2 | 2 | 0.95 |
 CH/LC | 37 | 20 |  |
